Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 20% in stock price compared to the market benchmark index within the next six months [6][17]. Core Viewpoints - The company is leading the global progress with its product AK112, which is expected to capture the largest market share in the second-generation IO market [2][4]. - The broad-spectrum anti-cancer effects of PD-1 and VEGF targets are promising, with a significant existing market potential of nearly 60 billion USD globally [3]. - The company has already received approval for two indications of AK112 in China, making it the only PD-1/VEGF dual antibody product available globally [4]. Financial Forecast and Valuation - Projected revenues for the company from 2025 to 2027 are estimated at 35.18 billion, 57.65 billion, and 93.72 billion CNY respectively, with net profits expected to be -1.86 billion, 8.03 billion, and 29.66 billion CNY [6][8]. - The estimated peak overseas sales for AK112, after risk adjustments, could reach approximately 197 billion USD [6]. - The report calculates a reasonable market value of 222.8 billion HKD based on a DCF valuation with a WACC of 8.06% and a perpetual growth rate of 1% [6].

周期、制造多主题走出主升形态 团队成员 策 略 研 究 投资要点： 策 略 定 期 报 告 主题投资数据库旨在筛选优秀量价形态的主题机会，把握热门主题的 见顶节奏、龙头股的调整程度。在 3/9 发布的《主题投资的下半场决胜法 则》中，我们构建了主题投资的数据追踪体系。我们专注于 2 方面：1）4 种形态量化筛选，高赔率的主题机会；2）构建交易热度指标，把握热门主 题的见顶节奏，并最新增加了龙头股的调整程度观察。后续，我们将定期 更新主题投资数据体系。我们希望通过这种偏量化的方式，给予投资者更 客观的参考，把握住主题投资的行情节奏。 周期、制造多主题走出主升形态。本期走出见底、突破、主升、加速 的主题指数数量分别有 0、3、25、0 只。其中，3 只突破形态的主题指数， 行业为有色金属、公用事业。25 只主升形态的主题指数，行业主要为机械 设备、电子、军工。 人形机器人、Deepseek 主题交易热度有所回暖，对应龙头股收盘价高 于 MA60 的位置。我们对人形机器人、Deepseek 主题进行交易热度的监控， 并且观察龙头股的调整程度。其中，人形机器人的交易热度回升至 80%， 长盛轴承的收盘价高于 MA60 ...

Group 1: UK Monetary Policy and Inflation - The Bank of England (BoE) faced challenges in lowering interest rates due to rising inflation expectations, ultimately deciding to cut rates by 25 basis points to 4.0% on August 7, 2025[3] - The BoE raised its food inflation forecast for Q3 2025 by 1.5 percentage points to 5.0%, expecting it to rise further to 5.5% by the end of 2025[3] - The nominal yield on 10-year UK government bonds increased by 323 basis points from February 1, 2022, to August 6, 2025, indicating a steepening yield curve[4] Group 2: US Tariff Impact and Economic Outlook - The implementation of "reciprocal tariffs" by the US is expected to impact global economies, with significant implications for non-US developed economies[5] - Initial jobless claims in the US rose by 0.7 thousand to 226 thousand, suggesting potential upward revisions in future employment data[5] - The US labor market shows signs of cooling, but strong consumer spending and non-residential investment contrast with the weak demand seen in the UK and other non-US developed economies[5] Group 3: Global Economic Trends - The recent tariffs imposed by the US range from 10% to 41%, affecting various trade partners, including China, and potentially leading to a restructuring of global supply chains[6] - The dollar index is expected to rebound after a temporary decline, which may put pressure on the Chinese yuan[6] - The report suggests that the People's Bank of China may consider a small rate cut of 10 basis points to stimulate demand in the real estate market[6]

Quantitative Models and Construction Methods 1. Model Name: Risk Factor Exposure Regression for Fixed Income+ Funds - **Model Construction Idea**: The model regresses the net asset value (NAV) of Fixed Income+ funds against pure style factor returns of various asset classes to determine the risk exposure of these funds to different asset categories [4][19] - **Model Construction Process**: 1. The NAV of Fixed Income+ funds is regressed on the pure style factor returns of various asset classes, including bonds, stocks, and convertible bonds [4][19] 2. For bond assets, the model identifies changes in duration and credit strategy exposure by comparing the average risk factor exposure between the current and previous months [4][19] 3. For convertible bonds, the model calculates the exposure to parity risk factors and tracks changes in overall positioning [4][23] - **Model Evaluation**: The model effectively captures the dynamic risk exposure of Fixed Income+ funds across different asset classes, providing insights into their allocation strategies [4][19] 2. Model Name: Fixed Income+ Fund Optimal Portfolio Construction - **Model Construction Idea**: The model selects 10 funds quarterly based on multiple dimensions such as win rate and odds, and allocates them equally to construct an optimal portfolio [5][26] - **Model Construction Process**: 1. Quarterly selection of 10 funds based on criteria such as win rate and odds [5][26] 2. Equal-weight allocation of the selected funds to form the optimal portfolio [5][26] - **Model Evaluation**: The constructed portfolio demonstrates more stable performance compared to the secondary bond fund index, outperforming it by 0.36% in the current month [5][27] 3. Model Name: Pure Bond Fund Optimal Portfolio Construction - **Model Construction Idea**: The model selects funds with alpha characteristics within one standard deviation of market averages across various style exposures and allocates them equally to construct an optimal portfolio [7][45] - **Model Construction Process**: 1. Identify funds with style exposures within one standard deviation of market averages [7][45] 2. Select 10 funds with high alpha characteristics on a quarterly basis [7][45] 3. Allocate the selected funds equally to form the optimal portfolio [7][45] - **Model Evaluation**: The portfolio outperformed the mid-to-long-term pure bond fund index by 0.16% year-to-date, demonstrating its effectiveness in generating excess returns [7][46] --- Quantitative Factors and Construction Methods 1. Factor Name: Bond Risk Factors - **Factor Construction Idea**: The factors include duration, slope, convexity, credit, and default, which are used to measure the risk exposure of pure bond funds [6][42] - **Factor Construction Process**: 1. Regress the NAV of pure bond funds on the five factors: duration, slope, convexity, credit, and default [6][42] 2. Analyze the mean changes in factor exposures between the current and previous months [6][42] 3. Assess the dispersion of factor exposures to evaluate consistency in fund strategies [6][42] - **Factor Evaluation**: The analysis reveals a significant increase in credit exposure and a decrease in convexity exposure, with low dispersion in credit exposure, indicating consistent adoption of credit strategies among funds [6][42] --- Backtesting Results of Models 1. Risk Factor Exposure Regression for Fixed Income+ Funds - No specific numerical backtesting results provided 2. Fixed Income+ Fund Optimal Portfolio Construction - Outperformed the secondary bond fund index by 0.36% in the current month [5][27] 3. Pure Bond Fund Optimal Portfolio Construction - Outperformed the mid-to-long-term pure bond fund index by 0.16% year-to-date [7][46] --- Backtesting Results of Factors 1. Bond Risk Factors - Credit exposure increased significantly, while convexity exposure decreased [6][42] - Low standard deviation in credit exposure indicates consistent strategy adoption [6][42]

Export Performance - In July, China's exports increased by 7.2% year-on-year, up 1.4 percentage points from June, continuing the improvement trend since May[1] - Exports to ASEAN rose by 16.6% year-on-year, while exports to South Korea increased by 4.6%, marking a significant recovery[2] - Exports to the US saw a decline of 21.7%, deepening by 5.5 percentage points compared to the previous month, indicating a stronger impact from tariffs[2] Import Trends - Imports in July rose by 4.1% year-on-year, a significant improvement of 3.0 percentage points, driven primarily by recovering crude oil prices[1] - The trade surplus narrowed slightly to $98.24 billion in July, reflecting the dynamics of both exports and imports[1] - The contribution of processing trade intermediate goods and capital goods imports fell by 0.6 percentage points, indicating a cooling in these sectors[5] Market Outlook - The extension of the tariff relief period by the US is expected to marginally boost exports of electromechanical products and mid-range consumer goods[6] - The imposition of 15% tariffs on other major trading partners may enhance China's export price competitiveness but could also weaken demand from these economies[6] - The semiconductor and machinery sectors may face challenges due to increased tariffs on key supply chain partners like Mexico and Vietnam[6]

Export Performance - In July, China's exports increased by 7.2% year-on-year, up 1.4 percentage points from June, continuing the upward trend since May[3] - Exports to ASEAN rose by 16.6% year-on-year, while exports to South Korea increased by 4.6%, marking a significant recovery[3] - Exports to the US fell by 21.7%, a decline deepening by 5.5 percentage points, indicating increased tariff impacts[3] Import Dynamics - Imports rose by 4.1% year-on-year in July, a significant improvement of 3.0 percentage points, driven primarily by recovering crude oil prices[4] - The decline in crude oil imports narrowed to 7.4%, improving by 6.8 percentage points compared to previous months[4] - However, imports of processing trade intermediate goods and capital goods saw a decline, contributing to a 0.6 percentage point drop[4] Trade Policy Implications - The US extended the tariff relief period for China by 90 days, which is expected to marginally boost exports of electromechanical products and mid-range consumer goods[5] - The imposition of 15% tariffs on other major trading partners may enhance China's export price competitiveness but could weaken demand from these economies[5] - The potential impact of increased tariffs on Mexico and Vietnam may affect China's semiconductor and machinery exports due to established supply chains[5] Risk Assessment - The report suggests that while a significant decline in exports is not anticipated, caution is advised due to the complex and evolving trade policy landscape[5] - There is a risk that global trade policy uncertainties could lead to lower-than-expected export growth[5]

AI UGC："Coding+多模态"重估平台价值 投资要点： 行 业 研 究 传媒 2025 年 08 月 07 日 快手可灵 2.0 为短视频 UGC 提质增效。2024 年 6 月推出可灵模 型，2025 年 4 月可灵发布 2.0 大师版，迭代一年月活用户增长 25 倍，全球用户突破 2200 万，累计生成视频超过 1.68 亿个、图片超过 3.44 亿张素材。通过可灵模型的赋能，短视频创作者极大提升内容生 产效率与视觉表现力，推动平台 UGC 视频质量与多样性提升。 华福证券 证 券 哔哩哔哩 AI 相关 UGC 内容高增。哔哩哔哩在 AI 相关内容的创 作与消费上持续高速增长。2025 年 Q1，平台 AI 相关视频观看时长 同比提升超 100%，吸引大量年轻用户涌入探索与学习 AI。平台内涌 现出涵盖 AI 绘画、视频生成 编程等多领域的创作社区，相关作品数 量和互动热度显著攀升，进一步巩固了其作为国内年轻用户聚集的 AI 内容创作与分享核心阵地的地位。 研 3、AI UGC 赋能 IP 开发平台：阅文集团 究 报 告 阅文集团计划运用 AI 对 IP 进行动漫化开发。阅文集团孵化大量 爆款头部 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [16]. Core Insights - The company's financial indicators have shown comprehensive improvement, with significant profit growth. For the first half of 2025, the company's revenue and net profit attributable to shareholders increased by 2.6% and 10.2%, respectively. In Q2, revenue and net profit grew by 4.0% and 26.9% year-on-year, reflecting an acceleration in growth compared to Q1 [3][4]. - Risk indicators continue to improve, providing room for profit release. By the end of Q2 2025, the non-performing loan balance and ratio decreased, with the non-performing loan ratio at 1.31%, down 2 basis points from Q1. The non-performing loan balance was 73.67 billion, a decrease of 0.61 billion from Q1 [4]. - The asset-liability structure has been optimized, leading to a narrowing decline in net interest margin. By the end of Q2 2025, loans increased by 6.0% year-on-year, and deposits grew by 12%, significantly outpacing total liabilities [5]. Financial Forecasts - The company is expected to achieve revenue growth rates of 3.0%, 4.2%, and 5.4% for 2025-2027, while net profit growth rates are projected at 11.2%, 5.3%, and 6.6% for the same period. The report maintains these forecasts from previous assessments [5][7]. - The report provides detailed financial projections, including operating revenue of 1759 billion in 2025, with a net profit of 503 billion, reflecting a growth rate of 11.22% [7][11].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][19] Core Insights - The company's performance in H1 2025 met expectations, with total revenue reaching 2.432 billion yuan, a year-on-year increase of 24.32%, and a net profit attributable to shareholders of 203 million yuan, up 42.56% year-on-year [3][4] - The domestic business is experiencing rapid growth, with significant contributions from core brands and product innovation [4][5] - The company has adjusted its profit forecasts upward, expecting revenues of 5.413 billion, 6.467 billion, and 7.667 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 465 million, 573 million, and 703 million yuan [6] Revenue Summary - In H1 2025, the company achieved revenue of 2.432 billion yuan, with snacks (including canned food) generating 1.53 billion yuan (up 6% year-on-year) and pet food revenue at 780 million yuan (up 86% year-on-year) [4] - Domestic revenue was 860 million yuan, reflecting a 39% year-on-year growth, while international revenue was 1.57 billion yuan, up 18% year-on-year [4] Profitability Summary - The company reported a gross margin of 31.4% in H1 2025, an increase of 3.4 percentage points year-on-year, with domestic gross margin at 38% and international gross margin at 28% [5] - The net profit margin for Q2 2025 was 8.4%, reflecting a year-on-year increase of 0.4 percentage points [5] Financial Forecasts - The company expects revenue growth rates of 21.2%, 19.5%, and 18.6% for 2025, 2026, and 2027 respectively, with net profit growth rates of 18.0%, 23.2%, and 22.8% for the same years [6] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.53 yuan, 1.88 yuan, and 2.31 yuan respectively [7] Valuation Metrics - The current stock price corresponds to price-to-earnings (P/E) ratios of 38x, 31x, and 25x for 2025, 2026, and 2027 respectively [6][7]

策 略 研 究 华福证券 2024 年抗肿瘤药物医保目录准入回顾 团队成员 投资要点： 抗肿瘤药医保准入持续加速，靶点加速覆盖、放量效应显著 2024 年新增 91 款药物中，抗肿瘤及免疫调节剂占 29 款、谈判品 种院端销售额 579 亿元，医保仍是创新药放量核心渠道。ALK 抑制剂、 EGFR TKI、HER2 ADC 医保覆盖率已达 100%，头部品种持续受益。 肺癌药物主导新增目录，癌谱覆盖仍存失衡 策 略 点 评 2024 年新增抗肿瘤药中肺癌领域占 11 款，而肝癌、胃癌、食管癌 无新药纳入。当前目录调整尚未匹配中国癌谱结构（肺癌占死亡 27.7%），结直肠癌等领域存在未满足需求。其他癌种创新药有望进入 医保，目录范围继续扩大。 高价疗法面临双重困境，支付模式亟待突破 CAR-T 定价远超医保隐形门槛，单次治愈特性难以分摊成本；叠 加技术迭代期过早纳入医保，可能引发基金穿底、企业回报压缩、患 者未来疗法缺失的风险。附条件批准的 CAR-T 普遍缺乏长期疗效与成 本效益数据，医保支持依赖真实世界证据验证。创新支付生态将成为 破局关键。 诚信专业 发现价值 1 请务必阅读报告末页的声明 分析师： 赵月 ...